Ambuja Cements Limited (AMBUJACEM) — Financial Results | 22 December 2025(2 announcements)

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
1 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

Ambuja Cements announced a strategic amalgamation of ACC Limited and Orient Cement Limited to create a unified cement platform with 107 MTPA capacity across 24 integrated units. The merger targets cost synergies of at least ₹100 per metric ton through network optimization and streamlined operations. Ambuja will issue 328 shares per 100 ACC shares and 33 shares per 100 Orient shares to eligible shareholders. Completion is expected within 12 months subject to regulatory approvals including NCLT and SEBI.

2 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

Ambuja Cements Limited's Board approved the amalgamation of ACC Limited and Orient Cement Limited, creating a unified cement platform with combined capacity targeting 155 MTPA by FY28. The merger will deliver cost synergies of at least ₹100 per metric tonne through optimized manufacturing, logistics, and reduced corporate overhead. ACC shareholders will receive 328 Ambuja shares (face value ₹2 each) per 100 ACC shares; Orient Cement shareholders will receive 33 Ambuja shares per 100 Orient shares. Subject to regulatory approvals, the transaction is expected to complete within one year.

About Ambuja Cements Limited (AMBUJACEM)

Construction Materials · Cement & Cement Products · Listed on NSE

Market Cap: ₹1,07,215.34 Cr P/E: 23.3 ROE: 7.7% ROCE: 4.6%

View full AMBUJACEM stock details →

📡 Get AI alerts when AMBUJACEM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AMBUJACEM — Free

📊 More AMBUJACEM filings

See all AMBUJACEM filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AMBUJACEM files new disclosures

Track AMBUJACEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AMBUJACEM — Free

Free account · 2 AI queries/day